CTT Pharmaceutical creates oral dissolvable strips for delivering nicotine, vitamins, and pharmaceuticals. The company uses a patented manufacturing process to produce thin polymer films that dissolve rapidly in saliva, providing a delivery alternative to traditional tablets or capsules. CTT is a development-stage entity with no current revenue, active manufacturing, or commercial products. Its strategy focuses on two near-term offerings: nicotine strips, positioned as a smokeless alternative to cigarettes, and vitamin strips. Nicotine strips require FDA approval before commercial sale in the U.S., while vitamin strips do not require similar authorization. CTT intends to generate revenue through direct retail sales, licensing agreements with global distributors, and strategic partnerships with pharmaceutical companies for prescription drug applications. The company’s core assets are patents protecting its delivery technology through the mid-2030s. CTT currently relies on equity financing to fund its operations and plans to use future capital to acquire manufacturing equipment and facilities. The company operates with a single full-time employee and faces a going concern qualification due to its lack of capital and commercial scale. CTT is attempting to transition from research and development to commercialization by targeting the oral nicotine and supplement markets.